Introduction
In recent years, Shiffman (Shiffman 2008; Shiffman et al. 2009 ) and others (OECD 2008; Sridhar and Batniji 2008; Ravishankar et al. 2009 ) have argued that global health financing has become increasingly skewed towards HIV/AIDS and to a lesser extent malaria and tuberculosis (TB). This pattern is reproduced at the national level in many countries. Studies of Mozambique, Uganda and Zambia have shown that a large proportion of health resources is being devoted to address HIV/AIDS in comparison with other disease areas (Oomman et al. 2008) . While some have argued that the spending on HIV/AIDS has been to the detriment of primary health care and has in fact weakened health systems, for example by taking away skilled staff from other sectors through higher salaries offered by donors (England 2007; Oomman et al. 2008) , others have noted that HIV/AIDS has brought attention to the importance of strengthening health systems and made new monies available for global health (Horton 2009) . The allocations at the country level have been explained by the donor-dependency of low-income countries, resulting in considerable influence of donor countries and multilateral institutions over country priority-setting in health (Global Economic Governance Programme 2008) . Do we see the same effect of international influence on budgetary allocation for health in middle-income countries?
Three countries that represent the core of the middle-income group are Brazil, Russia and India, members of the well-known BRIC group (with China). In each of these countries, health funding has become primarily endogenous and independent of external aid (Table 1, Figure 1 ). Each of their health care systems straddles provision for diseases across the epidemiological transition: having to provide services for both acute infectious diseases and chronic diseases associated with affluence. They have all embarked on a process of decentralization and reform of the health care sector; they all face the constraints of having to work with several states and hundreds of municipalities, scattered throughout a large geographical area; and they have large populations with high levels of income inequality. However, their political systems show some diversity. Brazil and India are two of the largest democracies, while Russia is one of the largest less democratic states.
Given that these nations are mostly aid-independent, that is, not significantly relying on donor aid and predominantly financing health through domestic sources, we test the assumption that there will be no biased response to any particular kind Figure 1 External resources for health as a percentage of total expenditure on health (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . Source: WHOSIS (WHO Statistical Information System), http://www.who.int/whosis/en/, 7 August 2009 Table 1 External resources for health as a percentage of total expenditure on health, Brazil, Russia, India and China, 1995 -2006 1995 1996 1998 1999 of disease and that health budgetary allocations will reflect the epidemiological burden of disease. This assumption is based on the higher likelihood that countries that are less dependent on aid are less constrained by donor aid assistance and are, consequently, much more autonomous in how they allocate funding (Buse and Walt 1997; Brautigam 2000; Brautigam and Knack 2004; Van de Walle 2005; Moss et al. 2006; Whitfield 2009 ). Because they receive far less funding for particular health sectors, such as AIDS, relatively compared with low-income countries, they are expected not to be as influenced by international pressures and biased in broader funding patterns. In the process of exploring the influence that global players have in setting health care priorities in these countries, we ask the following: 'how do country-level budgetary allocations compare with epidemiological estimates of burden of disease?' By relating disbursements to burden of disease, we create a baseline from which we can assess deviations in priority that may be due to influences other than epidemiological evidence. Underpinning the analysis is the question of whether Brazil, Russia and India have similar health financing patterns domestically to those observed globally. Analysing budgetary allocations in health is the first step to understanding the power relationships among various stakeholders at global, national and local levels, as well as the relative influence of power, ideas, institutions and culture in promoting investment and policy in certain health areas and not others (Gilson et al. 2008) . We look in particular at the major causes of burden of disease in each country, as well as the contribution that HIV/AIDS, TB and malaria make to the total burden of disease estimates. We focus on these three diseases because of their centrality on the global stage (Shiffman 2008; Ravishankar et al. 2009; Shiffman et al. 2009 ), demonstrated by the establishment of multilateral bodies such as the Global Fund to Fight HIV/AIDS, TB and Malaria (Global Fund) and UNAIDS, major bilateral programmes such as the President's Emergency Plan for AIDS Relief (PEPFAR) and the President's Malaria Initiative, and Millennium Development Goal 6 which focuses exclusively on combating HIV/AIDS.
Methods
Our purpose for comparing Brazil, Russia and India is not to illustrate or test the effectiveness of a generalizable theory about the determinants of domestic spending for diseases (Przerworski and Tuene 1970) , but rather to highlight each country's unique policy response (Skocpol and Somers 1980; Katznelson 1997) . Our goal is then to propose several hypotheses accounting for differences in spending outcomes. Instead of generating a new theory from our findings, we saw this as an exercise for creating new ideas, hypothesis-building and providing suggestions for new areas of research; others have noted that this is a benefit of conducting comparative case study analysis (Eckstein 1975; Abbot 1992) .
With regard to empirical data, to assess whether health allocations are aligned with epidemiological estimates for burden of disease, we used central government budgetary allocations through the Ministry of Health or its equivalent, e.g. National HIV/AIDS or TB programme. Information on health fundingthat is, the amount of money allocated from the federal budget for a particular disease-was sourced primarily from country-specific departments of finance and health, and when primary data were not available, from secondary sources. For Brazil and India, we used actual health budgets from the ministries of health and finance, respectively. As primary data were not available for Russia, we used World Bank summary data. Despite it being a key member of the BRIC group, China has been excluded from analysis and discussion in this paper. This is due to the absence of primary and secondary data for spending on each type of disease in China. We reviewed several prominent journal publications, such as The Lancet Special Series on China, as well as consulted senior academics and a consultant for the Ministry of Finance in China, but were not able to obtain the data on allocations.
Financial information is provided in standardized US$ dollar equivalents. To support the budgetary data, we also reviewed reports published by national governments, multilateral organizations and established academics to better understand the structure and flow of finances within each country's health system. In addition, for the Brazil and Indian case studies, we have drawn on interviews conducted with health officials and members of civil society by the authors of this paper. These interviews were conducted in July- Anand and Hanson (1997) , the use of DALYs is in line with previous analyses similar to our paper by Shiffman (2008) , Sridhar and Batniji (2008) and Ravishankar et al. (2009) . Age-standardized rates facilitate cross-country comparisons by adjusting for the differences in population structure between countries. It should be noted that while the most recent DALY data are from the 
Resource allocation versus burden of disease
The primary task undertaken in this paper is the comparison of financial allocations between those diseases that cause the greatest burden of disease and the 'Big 3' within the three countries.
Brazil
In Brazil, total government spending for health, as a percentage of total government spending, equalled 3. If measured using age-standardized DALY rates, several diseases emerge as the most burdensome in Brazil. The first is neuropsychiatric disorders, receiving a measure of 4337, per 100 000 in a population, followed by cardiovascular disease at 2537, then respiratory conditions and fourth unintentional injury at 1542 (Table 2, Figure 2 ). HIV/AIDS received a score of 229, followed by TB 164, and malaria 22. The burden of disease by HIV/AIDS, TB and malaria is much less when compared with other disease areas when measured in terms of DALYs.
Yet this does not seem to be reflected in the financing allocated to various disease areas. As Table 3 and Figure 3 demonstrate, the health conditions that are the most burdensome do not receive nearly as much funding from the federal government as HIV/AIDS. Even funding for TB was only US$10.8 million in 2002, climbing to US$26 million in 2006. Despite evidence of a co-infection problem with HIV as well as the emergence of multi-drug resistant TB (MDR-TB), these findings confirm the fact that TB has not been a priority for the government when compared with AIDS (Gómez 2007 With regard to the Ministry of Health's dependence on donor aid assistance, again the outcomes for each sector vary. When it comes to HIV/AIDS, the government has become less dependent on the World Bank and other creditors. In fact, congressional outlays for the AIDS programme have continued to increase and now far surpass the amount given by the World Bank: US$353.7 million from the government in 2001 versus a World Bank loan of US$28 million (which was that year's portion of a total loan package worth US$100 million signed in 1998); and US$741 million in 2008 versus a World Bank loan of only US$13.8 million that year (that year's disbursement of a total US$100 million loan signed in 2003) (Brazil Ministry In sum, despite Brazil's progressive universal health care system, it is clear that the burden of disease does not explain funding allocations. While HIV/AIDS is not even close to being as burdensome as neuropsychiatric disorders and chronic disease, it still receives much more domestic funding. Moreover, while Brazil is no longer dependent on donor aid for HIV/ AIDS-in fact, it is now starting to become a foreign aid donor, as evident through its recent contributions to the Global Fund Total spending for public health nevertheless declined during the 1990s and has not increased since then (Marquez 2005) . Most spending for public health occurs at the oblast (regional) level, which reflects the government's commitment to health policy decentralization, which started in 1993.
As Table 2 and Figure 2 demonstrate, when measured in terms of DALY rates, cardiovascular disease, neuropsychiatric disorders and unintentional injury are the most burdensome disease categories. Marquez (2008) notes that the government has allocated an estimated US$2.9 billion, or 20.8% of total federal health spending for hypertension, ischaemic heart disease and cerebrovascular disease. When combined, spending for cardiovascular, unintentional injuries and neuropsychiatric disorders assume more than 50% of the country's total health spending (Marquez 2008) . This is much higher than spending for other types of disease, such as HIV/AIDS, TB and malaria. Although new HIV cases did not begin to increase sharply until after 1998, there was nevertheless a sizeable increase in newly reported cases from 1995 until that period, increasing from 1090 in 1995 to 3971 in 1998, jumping radically to 19 758 in 1999 (World Bank 2009). However, no domestic funding for prevention or treatment emerged prior to 1998, which indicates an initial weak government response to the epidemic. Nevertheless, in 1998 federal funding commenced with an allocation of US$0.09 million, followed by US$1.3 million in 2000, and US$3.7 million in 2001, and it stayed at this level through to 2004. There was also a disparity in funding by each level of government. Finally, it has been noted that the lack of transparency about the HIV/ AIDS budget has led to the diversion of HIV/AIDS funding for other purposes (Vinokur et al. 2001) . While in recent years, essentially beginning in 2005, the government has publically announced its commitment to increase its funding for HIV prevention and treatment, it remains to be seen if it can follow through with its commitments (Kaiser Family Foundation 2005) . The Associated Press (2009) recently noted that since 2006, Russia has increased by 33 times its spending on AIDS programmes, but we are unable to verify this claim empirically.
With regard to TB, funding is minimal and new. Prior to 1999, there was no federal funding for TB (Vinokur et al. 2001) . Thereafter, approximately 90% of all funding for the production of drugs was provided at the oblast level. Federal spending for TB has gradually increased, but the bulk of all funding still comes from the state level. With regard to malaria, federal spending is essentially non-existent. This is due to the rapid decline in the number of cases since World War II. From 2001 to 2005, the total number of malaria cases dropped from 984 to 34 (WHO 2009a) . Funding allocations and commitment seem to reflect the low number of cases.
Government receptivity to donor assistance is minimal but has started to gradually increase. In 1996, US$18.3 million in aid was provided by all sources of foreign aid, increasing to US$65.8 million in 1999, yet this declined to US$30.9 million in 2001 (Twigg and Skolnik 2004) . In 1999, the World Bank began to work closely with the Ministry of Health for the implementation of a new TB programme, with HIV/AIDS being added later that year. In the same year, the World Bank offered a loan package of US$150 million, with US$100 million going towards TB and US$50 million to HIV/AIDS. After a long delay due Since 2001, the government has been more receptive to donor aid. The receipt of several grants to combat HIV/AIDS and TB since 2003 from the Global Fund provides a good example. Nevertheless, while this has helped to strengthen the TB and HIV/AIDS programme and kindled greater political commitment to combating these diseases, it is not clear that donor aid has shaped the historic evolution of Russia's AIDS and TB programme, or any other health programme for that matter. In fact, in 2006, Russia pledged that it would reimburse the Global Fund by 2010 for the US$270 million the country had received for HIV prevention and treatment programmes (Global Fund 2006; Global AIDS Alliance 2009) .
In sum, it seems that central government spending for disease reflects domestic need, rather than global priorities. This is evident through the secondary data which shows that more funding is allocated for the most burdensome diseases, such as cardiovascular diseases, neuropsychiatric disorders and unintentional injury, and not HIV/AIDS or TB. This, in turn, could reflect Russia's on-going decision to implement policies that do not reflect international pressures to conform to global priorities.
India
In India, total government spending for health, as a percentage of total government spending, equalled 3.6% in 2004, with household expenditure forming 73.5%. Central government expenditure formed 23% of government health spending, with state government expenditure being 77% (WHO 2006) . While health is constitutionally a state responsibility, it has been noted that despite only controlling 23% of the funds, central government sets the priorities in health which are executed by state governments (Berman and Ahuja 2008) . In addition, the central government dominates financing of public health and family welfare activities as well as centrally sponsored communicable disease programmes for HIV/AIDS, TB and malaria (Deolalikar et al. 2008) . Thus central government priorities in public health provide an important indicator of state priorities in public health.
If measured using age-standardized DALY rates, several disease areas emerge as the most burdensome in India. The first is cardiovascular disease at 3284, followed by neuropsychiatric disease at 3044, then respiratory conditions and then unintentional injury at 2913 (Table 2, Figure 2) . In contrast the DALY rates for HIV/AIDS, TB and malaria are 1011, 869 and 69, respectively.
How financing compares with the burden of disease is shown in Table 4 . HIV/AIDS receives a significantly higher allocation than all the other health areas, with a huge increase since 2004 (Figure 4) . HIV/AIDS has been addressed through the National AIDS Control Organisation (NACO) within the Ministry of Health and Family Welfare. External donors have played a significant role in funding NACO's National AIDS Control Projects (NACP) as well as providing technical assistance (Table 5, Figure 5 ). In the second phase of NACO (1999 NACO ( -2006 , the government only contributed 9.5% to the total budget, although by the third phase (2006-11) the percentage had increased to 40.8%. The total budget for the third phase is US$1484.96 million, which divided by 5 years equals roughly US$297 per year. In contrast, the National TB programme was allocated only US$39. 
Discussion
This comparative case study design illuminates some key similarities and differences in government response to various disease areas. It is important to note that there are several limitations to our work. The first is in terms of data availability. While two of the countries, Brazil and India, provide solid primary data on budgetary allocations for 2001-06, the other case, Russia, did not; this, in turn, reflects differences in government transparency. For Russia, secondary data provided by the World Bank allowed us to examine financing patterns; however, we are unable to verify how comparable this data is to that provided by the Brazilian and Indian governments. The second limitation relates to our focus on central government expenditure. This is in line with other analysts' work (WHO 2005) . Despite their lower share in financing compared with state/local expenditure, across the countries studied, central government expenditure provides a solid indication of priority-setting in health (see Deolalikar et al. 2008) . The third limitation relates to comparing the burden of disease and disbursements, as the cost per DALY gained is not equal for all diseases, with differences in cost-effectiveness of essential interventions. Additionally, other dimensions to resource allocation are equally, if not more, important than disease burden, and thus decisions should not focus solely on this measure. Finally, as noted in the methods section, we have relied on burden of disease data for 2001, which is the most recent data available, while budgetary allocations are for 2001-06.
By tracking the resources that Brazil, Russia and India have devoted to various disease areas, we can see that in Brazil and India there has been a bias in the level of investment in various health areas and convergence with global patterns of financing. HIV/AIDS, for example, seemed to obtain the most assistance from the federal government. And this occurred despite the fact that AIDS and other related disease, such as TB, were not the most burdensome. In contrast, Russia shows divergence from global patterns of financing, although with increased spending for HIV/AIDS and TB, this might be shifting slowly towards convergence.
We would like to put forth several factors that could explain the current bias in Brazil and India, but not yet in Russia. We build on Reich's framework of examining the state 'from above, from within, and from below'. Reich proposes a complex political ecology, where health policy emerges from the interaction of 'top-down' pressures from international actors, 'bottom-up' pressures from civil society and domestic government politics. We find his approach extremely useful in proposing what factors might be important in resource allocation other than disease burden. It is important to note that we are not testing the relative explanatory impact of each variable, as our goal is not to create and test a generalizable theory. Rather, we primarily draw on evidence from published sources as well as supporting data from primary interviews to describe what factors deserve further attention in understanding this puzzle (Box 1).
The first group of factors relates to those from 'top-down' pressures. The first factor we propose that might be important is the availability of external funding from multilateral banks, bilateral donors, philanthropists and public-private partnerships. Here, the World Bank and the Global Fund seem particularly important (Table 6, Table 7 ). Funding from the Bank for HIV/AIDS has acted, in certain country contexts, as a (Gauri and Lieberman 2006; Barbosa 2008, personal communication; Teixeira 2008, personal communication) . Similarly, although the first case of HIV was detected in India in 1986, it was only with a World Bank loan of US$84 million in 1991 that India's first National AIDS Control Project (1992 -1999 was launched with the objective of preventing new infections, raising awareness and increasing surveillance (Beck and Mays 2000; Sridhar 2009 ). External funding seems to be a crucial factor in explaining the relatively earlier convergence in Brazil and India. In both countries it seems that although external funding constitutes a fraction of the total health budget, it is being allowed to distort national priorities. As the former Director of NACO in India, K. Sujatha Rao, and colleagues note, 'Instead of the health system being strengthened by external funding, priorities get skewed and distortions created, as non-funded programmes, which could be equally if not more important, get lower funding priority' (National Commission on Macroeconomics and Health 2005). This shift in priorities has been expressed not only by the WHO (WHO 2009b), but also by several Indian non-governmental organizations (NGOs) and health experts who have argued that the emphasis on HIV/AIDS is detrimental to primary care and other communicable diseases (Chinai 2003) . In Russia, a similar concern emerged during the 1990s with donor assistance from the WHO, DFID, CIDA and the World Bank in 2003. However, this concern was temporary and quickly subsided as donor assistance did not skew domestic priority funding towards AIDS.
In contrast to Brazil and India, the World Bank played a more limited role in Russia in the 1990s (Twigg and Skolnick 2005) . Despite discussions with the World Bank during the latter part of the decade, the first World Bank loan to Russia for HIV/AIDS and TB was only made in 2003 in parallel with grants from the Global Fund (Table 7) . But as recent scholars note (Ancker 2008) , this funding has not motivated the government to increase domestic funding commitments to strengthen the Ministry of Health's AIDS Control Program, whether in the area of infrastructural capacity, coordination or resources for the states. Thus, even if World Bank funding had arrived earlier, this by no means suggests that AIDS programme expansion would have occurred at an earlier point in time. It remains to be seen whether external funding will have a future effect for HIV and TB. Yet Russia's response so far corroborates our point that while external funding is important, its positive and enduring consequences are not guaranteed and may only occur within certain historical and political contexts. We therefore consider other factors motivating government response.
A secondary factor related to external forces is the impact of the media coupled with recognition and attention from philanthropic institutions. This creates incentives for countries to focus on certain diseases at the expense of others. For example, in a recent Financial Times news article, the Executive-Director of the Global Fund, Michel Kazatchkine, called on emerging countries to fund HIV/AIDS activities using their own resources and to stop relying on external financiers (Jack 2008) . Similarly, the head of UNAIDS, Michel Sidibe, visited India in October 2009 and pushed the government to expand access to HIV treatment, to continue to expand its response to the HIV/ AIDS epidemic, as well as to start becoming a donor to UNAIDS (UNAIDS 2009a). Russia has also been pushed to expand its response to HIV/AIDS both in terms of quantity of financing and its HIV/AIDS prevention policy ( Adding to this, constant media reporting of 'successful' responses to HIV/AIDS may generate incentives for thriving middle-income nations to use this as a way to increase their international popularity and influence, as has been the case in Brazil (Teixeira 2007, personal communication; Passerelli 2009, personal communication) . Recognition from leading philanthropists, such as the Bill & Melinda Gates Foundation's granting of a formal prize to Brazil for having the best response to HIV/AIDS in 2003, creates ongoing incentives for the President, Congress and the Ministry of Health to invest more in HIV/AIDS policy at the expense of other diseases (Teixeira 2007, personal communication; Gómez 2009a) . Similarly, in 2003, the Gates Foundation entered India and established the US$258 million Avahan initiative, which is the largest HIV/ AIDS prevention programme in the world. Those close to the negotiations with the Indian government mention the key role the Gates Foundation played in lobbying for increased domestic attention to HIV/AIDS (Sridhar 2009 ); as one respondent noted, 'Bill pressed the government hard to allow a completely parallel programme -he had the clout from his relationships in the private sector with Microsoft.' Avahan is currently working closely with the NACO to transition the programme from the Gates Foundation to the government. Ashok Alexander, the head of Avahan, noted, 'We are not perpetual funders. We try to be catalytic' (Flock 2009 ). However, asking the government to assume the full cost of Avahan will result in an even higher proportion of funding being allocated to HIV/AIDS, and even the former head of the NACO, Sujatha Rao, remarked, 'We told them you can't create a huge number of assets and then just leave and expect the government to take over everything' (Flock 2009 ). To address the government's concern, the Gates Foundation donated an additional US$80 million for HIV/AIDS prevention, as well as praised the Indian government for their stellar response to the epidemic (Gates Foundation 2009). In Russia, the Gates Foundation has not directly set up operations or engaged with government, but rather made a US$44.7 million grant to Partners in Health to implement programmes to address TB.
A third top-down factor that might be important is a government's close relationship with UNAIDS, WHO and other UN bodies. Functions provided by UN bodies, such as surveillance, policy guidance and technical support for country planning for certain diseases, provide the necessary resources for domestic policy to follow global priorities (Gómez 2008) .
A particularly important in-country body is UNAIDS, which was created to advocate for increased institutional and financial commitment to HIV/AIDS, based on the premise that the disease is exceptional and thus deserves an exceptional response . In addition, as will be discussed below, strong partnerships between domestic health officials and officials in these agencies can lead to biased commitments to certain disease areas (Gómez 2009a ). This does not seem to be as significant a factor as external financing.
We now turn to look at factors within the state, particularly the political and bureaucratic incentives for reform and relationships between ministries. In some instances, biased attention to AIDS may reflect politicians' interest in using the popularity of AIDS as a platform for election (Whiteside 1999) . In other instances, politicians may wish to use AIDS policy in order to garner more political support, or use AIDS as a successful platform in order to increase their international influence through donor aid assistance. Since the mid-1990s, this was certainly the case in Brazil (Gómez 2009b; Passerelli 2009, personal communication) , and has started to emerge in India (Lieberman 2009 ). The absence of electoral accountability and competition in Russia has not yielded such a response (Wallander 2005) .
Similarly, increased international attention and resources for AIDS in the 1980s compared with other diseases has increased the legitimacy and influence of AIDS bureaucrats. The AIDS epidemic first emerged on the international agenda in 1985 with the creation of the WHO's Global Programme on AIDS, which was directed by the late Dr Jonathan Mann. In contrast, TB was not declared by the WHO as a 'global emergency' until 1993, while the WHO's Stop TB Partnership was only created in 1998. Similarly, international attention to malaria arguably did not begin until 1997 with the first International Conference on Malaria in Dakar, Senegal, and was further reinforced by the Abuja declaration in 2000, where African leaders affirmed their commitment to cutting malaria mortality by half by 2010 (Roll Back Malaria 2009) . In this situation where AIDS received earlier international recognition, domestic AIDS bureaucrats have had incentives to use their popularity and influence with the President or Prime Minister, who is supportive of international partnerships for AIDS policy, to obtain more support from the Congress or Parliament. This has certainly been the case in Brazil (Gómez 2007 ) and seems to also be true in India (Sridhar 2009 ). On the other hand, in Russia various factors have all contributed to AIDS officials' lack of popularity and influence. These include: Russia's more isolationist approach and tenuous partnerships with donors (Twigg and Skolnick 2004; Wallander 2005) , plus politicians' ongoing discrimination towards drug users and the gay community (Tkatchenko-Schmidt et al. 2008) , with the parliament being consistently influenced by the communist party and its close alignment with the Russian orthodox church, which is always adamantly opposed to sex education in schools and condemns HIV victims for behaving immorally (Chervyakov and Kon 1998) . This has not increased AIDS officials' ability to secure Presidential and Congressional support for more funding.
The third group of factors are 'bottom-up' pressures emanating from civil society activism. While there are civil society groups representing a host of disease areas ranging from diarrhoeal disease to malnutrition, HIV/AIDS activists tend to be better organized and financed (Barnett and Whiteside 1999) . HIV/AIDS groups have relatively more access to governments through national AIDS councils and legislative hearings (Loewenson 2003) , while having the ability to influence the global policy process through UNAIDS, the World Bank and the Global Fund, which all facilitate civil society-government engagements. While this is true in Brazil (Teixeira 1997; Filho 2006, personal communication; Terto 2006, personal communication) and India (UNGASS 2009), in Russia, the NGO movement is weak and based mainly at the state (oblast) level (McCullaugh 2005) . In Russia, in contrast to Brazil and India, there are no direct institutional linkages between national AIDS agencies and NGOs (Wallander 2005) . This might account for differences in effective lobbying pressures and budgetary allocations for HIV/AIDS between Brazil and India versus Russia.
Two additional factors explaining our findings cross-cutting all three levels are the strength of the private sector in health, specifically the pharmaceutical industry, and the influence of transnational advocacy movements for particular diseases. The pharmaceutical industry is expanding rapidly in all three countries. As of 2009, India's pharmaceutical market size is US$10.4 billion with annual growth of 8.4%, Brazil's is US$13.6 billion with growth of 5%, and Russia's is US$8.3 billion with 15.9% growth (Espicom 2009 ). The pharmaceutical industry has an incentive to lobby government towards treatment programmes, specifically in acquiring antiretrovirals for HIV/AIDS treatment programmes, rather than for prevention, or to address health issues, such as unintentional injury, where drugs are not the direct solution. This push for treatment is evident in Brazil, which provides free first-and second-line antiretrovirals, in India, which provides free first-line antiretrovirals, and in Russia, which has rapidly expanded treatment to those affected by HIV/AIDS. The private sector exerts influence not only within these three countries, but also in donor countries, as explored by Reich (2002) . It should be noted that it is not only the private sector that pushes for treatment, but also key multilaterals such as UNAIDS (e.g. by holding governments accountable for commitments to universal access to antiretrovirals) and WHO (e.g. through its 3 by 5 initiative), for both patented and generic drugs (UNAIDS 2009b).
The second major cross-cutting factor is the influence of transnational advocacy movements, specifically AIDS activist organizations. These organizations, largely based in the USA and Western Europe, have pushed donor governments to finance programmes for HIV/AIDS in low-and middle-income countries (Behrman 2004) , as well as provided financial and technical support to those local civil society organizations in line with their normative agenda (Sridhar 2009 ). The combination of pressure from donors through financing of particular diseases, from the pharmaceutical industry and from transnational advocacy movements across the three levels seems to be the key to understanding the convergence in Brazil and India with global priorities in health, namely HIV/AIDS, TB and malaria.
Conclusion
The findings in this paper raise issues for future research on the interactions between global, governmental and civic actors.
Although the results in this paper are preliminary, they indicate the need for further investigation into priority setting mechanisms at the national level instead of relying on the traditional explanation that the financial dependence of recipient countries on donors results in national budgetary allocations towards global priorities, such as HIV/AIDS. In particular more attention needs to be paid to the role that the international community plays in shaping domestic policy through identifying the various stakeholders and better understanding how they negotiate and interact. Our paper also indicates the need for further disclosure and transparency on budgetary allocations by the Russian government. While the findings in this paper should be relevant for those interested broadly in global health, they should be of particular interest to those working for key donors, multilaterals such as the UNDP, UNODC, WHO and UNAIDS, the Brazilian, Russian and Indian governments, and academics examining global health financing.
